(Q38047385)

English

Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

27 August 2017

Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network (English)

1 reference

Europe PubMed Central

27 August 2017

0 references

mantle cell lymphoma

1 reference

based on heuristic

inferred from title

Olivier Hermine

20

1 reference

Europe PubMed Central

27 August 2017

object named as

Pavel Klener

15

0 references

object named as

Eva Hoster

19

0 references

Annalisa Chiappella

object named as

Annalisa Chiappella

9

0 references

object named as

Sílvia Beà

3

0 references

Chan Yoon Cheah

object named as

Chan Cheah

8

0 references

object named as

Umberto Vitolo

14

0 references

Hanneke C Kluin-Nelemans

object named as

Hanneke C Kluin-Nelemans

2

0 references

Martin Dreyling

1

object named as

Martin Dreyling

1 reference

Europe PubMed Central

27 August 2017

Michael Unterhalt

17

object named as

Michael Unterhalt

1 reference

Europe PubMed Central

27 August 2017

author name string

Wolfram Klapper

4

1 reference

Europe PubMed Central

27 August 2017

Niclas Vogt

5

1 reference

Europe PubMed Central

27 August 2017

Marie-Helene Delfau-Larue

6

1 reference

Europe PubMed Central

27 August 2017

Grit Hutter

7

1 reference

Europe PubMed Central

27 August 2017

Sergio Cortelazzo

10

1 reference

Europe PubMed Central

27 August 2017

Christiane Pott

11

1 reference

Europe PubMed Central

27 August 2017

Georg Hess

12

1 reference

Europe PubMed Central

27 August 2017

Carlo Visco

13

1 reference

Europe PubMed Central

27 August 2017

Igor Aurer

16

1 reference

Europe PubMed Central

27 August 2017

Vincent Ribrag

18

1 reference

Europe PubMed Central

27 August 2017

European MCL Network

21

1 reference

Europe PubMed Central

27 August 2017

publication date

21 November 2012

1 reference

Europe PubMed Central

27 August 2017

Leukemia & Lymphoma

1 reference

Europe PubMed Central

27 August 2017

54

1 reference

Europe PubMed Central

27 August 2017

699-707

1 reference

Europe PubMed Central

27 August 2017

4

1 reference

Europe PubMed Central

27 August 2017

Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.733882

21 January 2018

Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.733882

21 January 2018

Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.733882

21 January 2018

Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.733882

21 January 2018

SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.733882

21 January 2018

Differential diagnosis of cyclin D2+ mantle cell lymphoma based on fluorescence in situ hybridization and quantitative real-time-PCR.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.733882

21 January 2018

Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.733882

21 January 2018

Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.733882

21 January 2018

Advances in the understanding of mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.733882

21 January 2018

Detection of gene copy number aberrations in mantle cell lymphoma by a single quantitative multiplex PCR assay: clinicopathological relevance and prognosis value

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.733882

21 January 2018

Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.733882

21 January 2018

Signal transduction inhibitor therapy for lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.733882

21 January 2018

CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.733882

21 January 2018

CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.733882

21 January 2018

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.733882

21 January 2018

CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.733882

21 January 2018

Central nervous system involvement in mantle cell lymphoma.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.733882

21 January 2018

Central nervous system involvement in patients with mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.733882

21 January 2018

Cerebrospinal fluid involvement in mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.733882

21 January 2018

Mantle cell lymphoma with central nervous system involvement: frequency and clinical features

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.733882

21 January 2018

Outcome of deferred initial therapy in mantle-cell lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.733882

21 January 2018

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.733882

21 January 2018

Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen).

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.733882

21 January 2018

Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.733882

21 January 2018

Treatment of elderly patients with mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.733882

21 January 2018

Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.733882

21 January 2018

Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.733882

21 January 2018

Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.733882

21 January 2018

The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.733882

21 January 2018

Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.733882

21 January 2018

The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.733882

21 January 2018

Genomic and Gene Expression Profiling Defines Indolent Forms of Mantle Cell Lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.733882

21 January 2018

Identifiers

10.3109/10428194.2012.733882

1 reference

Europe PubMed Central

27 August 2017

1 reference

Europe PubMed Central

27 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38047385&oldid=2092777235"